Feline Aortic Thromboembolism: Clopidogrel vs Aspirin Trial: FATCAT (Study Closed)
You do not have permission to view this document: [5930814]!
Proceedings for this trial can be found here
Study Start Date: 04/01/2006
Study End Date: 12/31/2010
Feline Aortic Thromboembolism: Clopidogrel vs Aspirin Trial: FATCAT
Feline aortic thromboembolism (FATE) is a devastating disease of cats usually associated with severe heart disease. The condition has a greater than 50% acute mortality, and a large number of cats that survive the acute embolic event, suffer a recurrence. This study is aimed at examining whether clopidogrel, a platelet activation inhibitor, can reduce the incidence of recurrence in cats that have survived an initial event, compared to aspirin.
Full study details are available at the FATCAT website
Inclusion criteria:
1) Cats with confirmed cardiogenic FATE that have survived for at least 1 month, but not more than 3 months, after the acute event.
2) Echocardiographic diagnosis of cardiac disease
3) Fully informed owner consent.
Exclusion Criteria:
Cats with non-cardiogenic FATE; cats that have not met the temporal inclusion criteria; documented taurine deficiency, bleeding disorders including thrombocytopenia, thrombocytopenia without bleeding, presence of an intracardiac thrombus, unstable congestive heart failure and concurrent conditions (non-cardiac) that would likely result in death in less than 1 year.
Study Controls:
Cats will be randomly assigned to receive either clopidogrel or aspirin.
Study Sample Size:
40 cats
Study Endpoints:
Primary endpoint: recurrence of FATE
Secondary endpoints: Survival / all-cause mortality, cardiac mortality. CHF is a secondary endpoint that does not exclude continuation.
You do not have permission to view this document: [5923816]!
Costs/Reimbursements:
Office calls (3 per cat) $50 ea.
Echocardiogram (1 per cat) $250 ea.
CBC (2 per cat) $35 ea.
Serum Chemistry (3 per cat) $55 ea.
Study Drugs (clopidogrel or aspirin) supplied by principal investigator.
This document was revised on: 1/7/2015